Related Experiment Video
Updated: Aug 22, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
New drugs for Gram-positive uropathogens
1Department of Urology, Hospital St. Elisabeth, St. Elisabeth Strasse 23, D-94315 Straubing, Germany.
Abstract:
Complicated urinary tract infections (UTIs) are frequent nosocomial infections. The bacterial spectrum encompasses Gram-negative but also Gram-positive pathogens in up to 30-40%. The existing treatment for Gram-positive pathogens is not always optimal. Antimicrobials for the treatment of Gram-positive uropathogens comprise older agents, such as aminopenicillins with or without beta-lactamase inhibitors and vancomycin, as well as newer fluoroquinolones, such as levofloxacin or gatifloxacin. However, resistant bacteria such as vancomycin-resistant enterococci (VRE) or methicillin-resistant Staphylococcus aureus (MRSA) (except vancomycin-resistant) are generally also not susceptible to the fluoroquinolones. Therefore new agents need to be assessed in the treatment of UTI. Daptomycin and linezolid are new antimicrobial agents with good efficacy against Gram-positive uropathogens as shown by their minimal inhibitory concentrations. In a phase II study the urinary bactericidal activity of linezolid versus ciprofloxacin in volunteers showed comparable activity of both drugs against fluoroquinolone susceptible Gram-positive uropathogens, whereas linezolid was also as active against fluoroquinolone resistant ones. The pharmacokinetics and the mode of action of these two antibiotics are discussed together with some clinical data in the context of therapeutic use in patients with complicated UTIs.
Insights
New antibiotics like linezolid show promise for treating complicated urinary tract infections (UTIs) caused by resistant Gram-positive bacteria. They offer an effective alternative when older treatments fail.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Complicated urinary tract infections (UTIs) are common hospital-acquired infections.
- Gram-positive pathogens account for 30-40% of UTIs, with increasing resistance to current treatments.
- Existing therapies for Gram-positive uropathogens, including older agents and fluoroquinolones, face limitations against resistant strains like VRE and MRSA.
Purpose of the Study:
- To assess the efficacy of new antimicrobial agents against Gram-positive uropathogens in complicated UTIs.
- To compare the urinary bactericidal activity of linezolid and ciprofloxacin in a Phase II study.
- To discuss the pharmacokinetics, mechanism of action, and clinical data of daptomycin and linezolid for UTI treatment.
Main Methods:
- Phase II study in volunteers to evaluate urinary bactericidal activity.
- Comparison of linezolid and ciprofloxacin against Gram-positive uropathogens.
- Analysis of pharmacokinetic and pharmacodynamic properties of new agents.
Main Results:
- Linezolid demonstrated comparable activity to ciprofloxacin against fluoroquinolone-susceptible Gram-positive uropathogens.
- Linezolid maintained activity against fluoroquinolone-resistant Gram-positive uropathogens.
- New agents like daptomycin and linezolid show good efficacy based on minimal inhibitory concentrations.
Conclusions:
- Linezolid presents a viable therapeutic option for complicated UTIs caused by fluoroquinolone-resistant Gram-positive bacteria.
- Further clinical data is needed to fully establish the role of daptomycin and linezolid in managing complicated UTIs.
- The study highlights the need for novel antimicrobial strategies to combat resistant uropathogens.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Inhibitors of Gram-positive Cell Wall Synthesis
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Bacterial DNA Synthesis
Urine Studies II: Urine Culture and Sensitivity Test